Observational studyDiabetes, obesity & metabolism2025

Post-authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi-country European study.

Niklas Schmedt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.